Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurotec for fibromyalgia syndrome
ACTRN12609000065291Phase 3Not yet recruiting
- Sponsor
- Iran Rheumatology Center
- Start
- Nov 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of Neurotec in fibromyalgia (FM) (2 arms), sponsored by Iran Rheumatology Center. Primary endpoints: Number of tender points and Pain severity. Planned start Nov 2008; status: not yet recruiting.
02
Drugs
Neurotec
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on ACTRN12609000065291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000065291.